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Abstract
THE SMALL MOLECULE BCL-2 INHIBITOR HA14-1 POTENTIATES THE
LETHALITY OF A REGIMEN COMBINING MEK1/2 AND CHK1 INHIBITORS
IN MULTIPLE MYELOMA CELLS
by Leena E. Youssefian, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Director: Dr. Steven Grant, M.D.
Professor, Department of Medicine, Biochemistry, and Pharmacology

Previously, we have found that the co-administration of MEK1/2 inhibitors and
Chk1 inhibitors synergistically induce multiple myeloma cell apoptosis through
upregulation of the BH3-only pro-apoptotic protein Bim. However, these apoptotic
events were largely blocked by the characteristic over-expression of Bcl-2 of Bcl-xL in
multiple myeloma cells. HA14-1, a small molecule Bcl-2 inhibitor, may therefore
circumvent this resistance to apoptosis by blocking Bcl-2 and Bcl-xL anti-apoptotic
protein actions. In our project, we hypothesize that the co-administration of HA14-1 with
MEK/Chk1 inhibitors will enhance apoptosis in multiple myeloma (MM) cells. To test
this hypothesis, we exposed MM cells U266 and RPMI8226, or those cells with Bcl-2
over-expressing stable clones to minimally toxic concentrations of MEK1/2 inhibitor
(PD184352) with Chk1 inhibitor (CEP3891) for 24 hours, followed by the Bcl-2 inhibitor
(HA14-1). To date, our data indicates that co-administration of HA14-1 with the
PD184352/CEP3891 regimen significantly enhances apoptotic death in U266/Bcl-2

v

multiple myeloma cells compared with the PD184352/CEP3891 regimen. Future studies
are designed to elucidate mechanisms underlying Bcl-2 and Bcl-xL anti-apoptotic protein
interactions with the Bak and Bim apoptotic proteins, focusing release of Bak and Bim
from Bcl-2/Bcl-xL, and subsequent Bax/Bak activation.
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INTRODUCTION
1.1 Cell Survival vs. Apoptosis
Normal cells have the propensity to either live or die. Depending upon cellular
conditions, there are three known mechanisms leading to cell death: apoptosis, necrosis,
and autophagy. Cells may also be abrogated in various stages of the cell cycle, such as
G0, thereby maintaining a quiescent, non-proliferative state.1
Apoptosis is a process of programmed cell death which occurs during the course
of normal development and maintenance of the mammalian anatomy. It is characterized
by typical morphological and biochemical hallmarks including, cell shrinkage, DNA
fragmentation, chromatin condensation, and plasma membrane blebbing.1,2,3 Activation
of caspase proteins is the major characteristic of apoptosis. Caspases can be activated
through two distinct routes: an extrinsic pathway, involving death receptors, or an,
intrinsic pathway which involves the mitochondria.4 The extrinsic pathway, or the death
receptor pathway, induces apoptosis through stimulation of death receptors of the TNF
(tumor necrosis factor) receptor superfamily, such as CD95 (APO-1/Fas) or TRAIL
(TNF-related apoptosis inducing ligand) receptors. These receptors are activated by
CD95-L (CD95 ligand) and TRAIL, respectively. The activated receptors result in
receptor aggregation and recruitment of FADD (Fas-associated death domain), an adaptor
molecule, and caspase-8. Upon recruitment, caspase-8 becomes activated and initiates
apoptosis by direct cleavage of downstream effector caspases.2,3 The determination of a
cell to survive or undergo apoptotic death through the intrinsic pathway is regulated by
the Bcl-2 (B-cell CLL/lymphoma2) family proteins.5
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1.2 Growth and Proliferation of Multiple Myeloma Cells
Multiple myeloma (MM) is a generally incurable plasma cell disorder originating
in the bone marrow. It arises from the dysregulated proliferation and survival of
differentiated plasma cells. As shown in Figure 1, growth and survival of MM cells relies
on IL-6 (interleukin-6) and IGF-1 (insulin-like growth factor-I), which promote upregulation of anti-apoptotic proteins.6 As a consequence, these cells exhibit high levels of
the anti-apoptotic Bcl-2 family proteins, particularly Bcl-2, Bcl-xL, and Mcl-1.

BCL-2

2002, Anderson KC (Revised)
Figure 1. Growth and proliferation of multiple myeloma cells relies on the interactions of the
extracellular IL-6 and IGF-1 signals with the cell surface protein receptors on MM cells.
These interactions elicit cascade signals in the Raf/MEK and JAK/STAT pathways, which
promote up-regulation of anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 to generate
resistance to apoptosis.

The Bcl-2 family proteins play a key role in regulation of the intrinsic pathway of
apoptosis through Mitochondrial Outer Membrane Permeabilization (MOMP). Normal
cells display a delicate balance between pro-apoptotic and anti-apoptotic Bcl-2 family
proteins. The pro-apoptotic proteins such as Bax, Bak, and Bim promote the deadly fate
of a cell while the anti-apoptotic proteins such as Bcl-2, Bcl-xL, Mcl-1 and Bcl-w,
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function to keep the cell alive.4 The functionality of these proteins is determined by their
BH (Bcl-2 homology) domains (Figure 2).

Figure 2. The Bcl-2 family of proteins is comprised of anti-apoptotic and pro-apoptotic
proteins. The anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL, and Mcl-1) have BH (Bcl-2
homology) domains 1-4. There are two classes of pro-apoptotic proteins; one class (including
Bax and Bak) has BH domains 1-3 and the other (designated BH3-only proteins, e.g., Bim)
has only the BH3 domain.4

Mechanistically, during stress or cellular damage, BH3-only proteins become
activated. Certain BH3-only proteins, such as Bim, activate the pro-apoptotic Bcl-2
family proteins Bax (Bcl-2-associated-X protein) or Bak (Bcl-2-agonist killer).4
Activated Bax and Bak proteins homo-oligomerize and form a pore in the outer
mitochondrial membrane. This pore allows for the escape of the pro-apoptotic molecule
cytochrome c. The escape of cytochrome c is the major initiator of the intrinsic pathway
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of apoptosis.7 Cytochrome c activates caspase-9 which in turn activates caspase-3 leading
to cleavage of key cellular proteins downstream, such as the DNA repair protein PARP
(Poly ADP-ribose polymerase). These events are the underlying mechanisms that are
known to promote apoptosis (Figure 3).4,8

Figure 3. In a healthy cell, the anti-apoptotic protein Bcl-2 is localized on the surface of the
mitochondrial outer membrane. It interferes with Bax/Bak homo-oligomerization and
thereby prevents apoptosis mediated by the mitochondria-dependent intrinsic pathway. In
an apoptotic cell, Bcl-2 is bound by BH3-only proteins. As a consequence, Bax and Bak are
unleashed from the sequestration of Bcl-2. Bax/Bak then homo-oligomerize to form a pore
for the release of cytochrome c that subsequently forms an apoptosome in which caspase-9 is
activated.
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1.3 The Importance of Bim
Growth factor deprivation, noxious stimuli, and chemotherapeutic agents such as,
glucocorticoids, Gleevec, and paclitaxel induce cell death through the activation of the
intrinsic pathway of apoptosis. These agents activate Bim, a BH3-only apoptotic protein
critical for the initiation of apoptosis. Bim is widely expressed in multiple tissues
including hematopoietic stem cells. As a product of alternative splicing, Bim exists as at
least 3 isoforms: BimEL, BimL, and BimS.9 The function and expression of Bim is
regulated at two levels: transcriptionally and post-translationally.10 The most abundant
isoform of Bim is BimEL.11,12 In viable cells, BimEL is known to be localized on the
mitochondrial outer membrane and is believed to be bound to anti-apoptotic proteins Bcl2, Bcl-xL, and Mcl-1.13 These anti-apoptotic proteins sequester BimEL and keep it in its
inactive form. Furthermore, post-translational regulation of BimEL is primarily mediated
by ERK1/2 (extracellular signal-regulated kinase).11 Multiple phosphorylations of BimEL
by ERK1/2 initiates ubiquitination and proteosomal degradation of BimEL.14,15

1.4 The Strategy Combining MEK1/2 and Chk1 Inhibitors: A Potential Therapy for
Multiple Myeloma
Since BimEL plays a major role in apoptosis, previously, our group has
investigated the role of BimEL in synergistic interactions mediating apoptosis between
agents targeting checkpoint kinase 1 (Chk1, eg., UCN-01) and mitogen-activated protein
kinase kinase 1/2 (MEK1/2, e.g., PD184352) respectively.8
UCN-01 (7-hydroxystaurosporine) is a derivative of the kinase inhibitor
staurosporine. Although, it was originally developed as protein kinase C inhibitor, it has
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subsequently been shown to inhibit the activity of Chk1 as well as other kinases. 16,17,18 At
nanomolar concentrations, UCN-01 induces apoptosis in malignant hematopoietic cells.19
Previously, our group reported that exposure of human leukemia and myeloma
cells to UCN-01 at subtoxic concentrations, induces phosphorylation and marked
activation of MEK1/2 and ERK1/2. This event was significantly blocked by the MEK1/2
inhibitor PD184352. Furthermore, co-administration of PD184352 highly synergistically
potentiated apoptosis induced by UCN-01. However, the mechanism by which ERK1/2
inactivation enhances apoptosis in this situation has not been fully defined.8,20,21 Further
studies regarding the implications of the enhancement of apoptosis in MM cells with this
regimen have led us to discover that perturbations in BimEL phosphorylation play a
significant functional role in this process.8
The interaction between MEK1/2 inhibitors and Chk1 inhibitors to synergistically
induce multiple myeloma cell apoptosis may also involve down-regulation and/or
inhibition of anti-apoptotic proteins.8 As mentioned earlier, one of the characteristics of
multiple myeloma cells is that they rely on IL-6 and IGF1 for survival. As a consequence,
they exhibit a high expression of the Bcl-2, Bcl-xL, and Mcl-1 anti-apoptotic proteins.13
The high expression of these anti-apoptotic proteins in cells accounts for one of the major
mechanisms by which these cells display resistance to the conventional treatments for
hematological malignancies.22 These anti-apoptotic Bcl-2 family proteins act to prevent
MOMP and the release of cytochrome c from the mitochondria by sequestering Bax /Bak
homo-oligomerization to form a pore on the mitochondrial outer membrane.23 Since the
combination regimen of PD184352/UCN-01 induces apoptosis primarily via the
mitochondria-dependent intrinsic pathway, this event is largely blocked by the ectopic
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over-expression of Bcl-2 or Bcl-xL in MM cells.24,25 Such findings raise a possibility that
the combination therapy of MEK1/2 inhibitors and Chk1 inhibitors may not efficiently
kill tumor cells bearing those high levels of Bcl-2. In other words, interruption of Bcl-2
function may be required for the restoration of tumor cell sensitivity to the MEK1/2/Chk1
inhibitor regimen, particularly in the cells harboring over-expression of Bcl-2.

1.5 Applications of HA14-1 in Bcl-2 Over-expression in MM Cells
The small-molecule inhibitor HA14-1 functions as a Bad mimetic. It has the
capacity to bind to the Bcl-2 surface pocket and disrupt its association with apoptotic
proteins such as Bax or Bak.26 Previously our group has shown that HA14-1, in
combination with the CDK inhibitor flavopiridol, effectively triggers oxidative injury,
mitochondrial dysfunction, caspase activation, and apoptosis in multiple myeloma cells
(including those resistant to conventional therapeutic agents such as dexamethasone,
melphalan, and doxorubicin).24
HA14-1, as a small molecule Bcl-2 inhibitor, may circumvent the Bcl-2 mediated
resistance of MM cells to apoptosis induced by the Chk1/MEK1/2 inhibitor regimen.
Theoretically, HA14-1 may act to block anti-apoptotic protein actions of Bcl-2 and BclxL which represent a major roadblock to the Chk1/MEK1/2 inhibitor strategy. In this
project, we are attempting to test whether HA14-1 in conjunction with the MEK1/2
inhibitor PD184352 and the novel, highly selective Chk1 inhibitor CEP3891 is able to
promote apoptosis in MM cells that ectopically over-express Bcl-2. CEP3891, as a highly
selective Chk1 inhibitor, is currently under preclinical evaluation, which has been found
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to potentiate the lethal effects of DNA-damaging agents by abrogating both G2-M and
G1 checkpoints.27,28

1.6 Objectives
A. PD184352 and CEP3891 will synergistically induce apoptosis in MM cells,
which will be prevented by ectopic over-expression of Bcl-2.
B. Co-administration of HA14-1 with a regimen combining MEK1/2 and Chk1
inhibitors will promote apoptosis in MM cells by circumventing the cytoprotective
effects of Bcl-2 over-expression.
C. The underlying mechanism involving this phenomenon may be related to
BimEL up-regulation and simultaneous disabling of both Mcl-1 and Bcl-2, which leads to
unleashing and activation of Bax and Bak, thereby triggering MOMP and apoptosis.

MATERIALS AND METHODS
2.1 Cells and Reagents
The human MM cell lines U266 and NCI-H929 were purchased from ATCC
(Rockville, MD) and maintained as described earlier.21 RPMI8226 cells were kindly
provided by Dr. Alan Lichtenstein (UCLA, LA), and cultured as reported previously.26
All experiments were performed using logarithmically growing cells (4 ×105 to 6 ×105
ml).
The selective MEK inhibitor PD184352 was purchased from Upstate Biotechnology
(Lake Placid, NY). The specific Chk1 inhibitor CEP3891 was provided by Cephalon, Inc.
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and used at a concentration of 400-500 nM/L. Cell-permeable, low-molecular-weight
Bcl-2 inhibitor HA14-1 was purchased from Biomol (Plymouth Meeting, PA, USA).
Reagents were dissolved in sterile DMSO and stored frozen under light protection at 20°C. In all experiments, final concentrations of DMSO did not exceed 0.1%.

2.2 Plasmids and Transfection
cDNAs encoding mouse (Upstate Biotechnology) and human full-length Bcl-2
were cloned into pUSE vectors. Transfections were performed using an Amaxa
Nucleofector device and Cell Line Specific Nucleofector Kits (Amaxa, Cologne,
Germany) per the manufacturer's instructions: Kit V/program G-015 for RPMI8226 and
Kit C/program X-005 for U266. For stable transfections, cells were continuously cultured
under selection with G418 (750 μg/ml for RPMI8226, or 400 μg/ml for U266).

2.3 Experimental Format
All experiments were performed utilizing logarithmically growing cells (4-6×
105cells/ml). Cell suspensions were placed in sterile FALCON tissue culture dishes (Becton
Dickinson, Franklin Lakes, NJ, USA) for 24h, and then incubated with PD184352 and CEP3891 for 24 h at 37 oC. At the end of this period, HA14-1 was added to the suspension, and
the dishes placed in a 37 oC, 5% CO2 incubator for various intervals. After drug treatment,
cells were harvested and subjected to further analysis as described below.
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2.4 Mitochondrial Membrane Potential (

m)

Assay

After drug treatment, cells (2 ×105) were incubated with 40 nM/L 3,3dihexyloxacarbocyanine (DiOC6, Molecular Probes Inc., Eugene, OR, USA) in PBS at
37oC for 20 minutes and then analyzed by flow cytometry. The percentage of cells
exhibiting low level of DiOC6 uptake, which reflects loss of mitochondrial membrane
potential, was determined using Becton-Dickinson FACScan (Becton-Dickinson, San
Jose, CA, USA).

2.5 Assessment of Cell Death
After drug treatment, cell death was assessed by 7-AAD staining (0.5 µg/ml 7AAD at 37°C for 30 minutes) and flow cytometry analysis.

2.6 Western Blot Analysis
Western blot samples were prepared from whole-cell pellets using Triton X-100
buffer as described previously.26 Amount of total protein was quantified using Coomassie
Protein Assay Reagent (Pierce, Rockford, IL). Equal amounts of protein (20 μg per
condition) were separated on precast sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels (Invitrogen, Carlsbad, CA) and electro-transferred onto
nitrocellulose membranes. For detection of phosphorylated proteins, no SDS was
included in the transfer buffer, and Tris-buffered saline (TBS) was used throughout. Blots
were probed with primary antibodies as follows. Blots were re-probed with anti-actin
(Sigma) or anti-tubulin antibody (Oncogene, San Diego, CA) to ensure equal loading and
transfer of proteins. Primary antibodies included anti-phospho-p44/42 (Thr202/Tyr204)
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MAPK

(ERK1/2)

poly(ADPribose)

and

anti-p44/42

polymerase

(PARP)

MAPK

(Cell

antibody

Signaling,

(Biomol),

Beverly,

anti-caspase-3

MA),
(BD

Transduction Laboratories), anti-cleaved caspase-3 (17 kDa) (Cell Signaling), anticaspase-9 (BD PharMingen), anti-cleaved caspase-9 (35 kDa ) (Cell Signaling), antiBimEL (Calbiochem), anti-mouse Bcl-2 (CHEMICON International, Inc., CA), and antihuman Bcl-2 oncoprotein (DAKO, Carpinteria, CA).

2.7 Statistical Analysis
For flow cytometric analyses of DiOC6 and 7-AAD, values represent the means
(± SD) for at least 3 separate experiments performed in triplicate experiments. The
significance of differences between experimental variables was determined using the
Student t-test.

RESULTS
3.1 Ectopic Over-expression of Bcl-2 in MM Cells Blocks Cell Death Induced by
MEK1/2 and Chk1 Inhibitors
To test whether Bcl-2 over-expression blocks apoptosis when co-exposed to
minimally

toxic

concentrations

of

the

Chk1

and

MEK1/2

inhibitors

(CEP3891/PD184352), we employed U266 cells that ectopically over-express mouse
Bcl-2 in comparison with their parental cells. We observed a dramatic increase in cell
death of U266 cells when exposed (48 hours) to minimally toxic doses of a combination
of the novel Chk1 inhibitor, CEP3891 (400 nM) with PD184352 (5 μM) (Figure 4A). The
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same regimen administered in Bcl-2 over-expressing U266 cells showed significantly
reduced mitochondrial membrane potential loss in comparison to the parental cells
(P<0.001) (Figure 4B). Consistent with previous results,8,20 these results indicate that coadministration of the Chk1 inhibitor CEP3891 with PD184352 synergistically induces
apoptosis in U266 cells, while over-expression of Bcl-2 largely blocks these apoptotic
events. Therefore, the anti-apoptotic protein Bcl-2 functions to block mitochondrial
damage and cell death induced by the CEP3891/PD184352 regimen.

12

Figure 4. Ectopic over-expression of Bcl-2 in these multiple myeloma cells blocks cell death
and events of MOMP induced by MEK1/2 and Chk1 inhibitors. Panel A shows the
percentage of parental U266 cells undergoing mitochondrial outer membrane
permeabilization (MOMP) (top left) and Cell Death (bottom left) under four different
conditions. Panel B shows the percentage of Bcl-2 over-expressing U266 cells undergoing
mitochondrial outer membrane permeabilization (MOMP) (top right) and Cell Death
(bottom right) under the same four conditions. All cells were incubated with the MEK1/2
inhibitor, PD184352, and the Chk1 inhibitor, CEP3891, for 48 hours before results were
analyzed. The Bcl-2 over-expressed cells display a lower incidence of MOMP and cell death
under each condition compared to the parental U266 cells.
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3.2 Co-administration of HA14-1 with a Regimen Combining MEK1/2 and Chk1
Inhibitors Promotes Cell Death in MM Cells
To test whether HA14-1 antagonizes Bcl-2 to further enhance cell death induced
by the CEP3981/PD184352 regimen, we exposed parental U266 cells to sub-toxic
concentrations of the CEP3891/PD184352 regimen for 24 hours, followed by coadministration of HA14-1 (2.5 μM; 24 hours). Treatment of the U266 cells with the
CEP3891/PD184352/HA14-1 combination resulted in a greater promotion of apoptosis
compared to the CEP3891/PD184352 regimen (Figure 5A). These results were further
confirmed in two other myeloma cell lines: RPMI8226, CEP3891 (500 nM)/ PD184352
(2.5 μM) / HA14-1 (1 μM) and H929 (500 nM)/ PD184352 (2.5 μM) / HA14-1 (2.5 μM)
(Figure 5B,C).
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Figure 5. HA14-1 enhances lethality of the PD184352/CEP3891 regimen in MM cells. Panel
A shows the percentage of parental U266 cells undergoing mitochondrial outer membrane
permeabilization (MOMP) (top left) and Cell Death (bottom left) under four different
conditions. Panel B shows the percentage of 8226 cells undergoing mitochondrial outer
membrane permeabilization (MOMP) (top center) and Cell Death (bottom center) when
treated with the same three drugs. Panel C shows the percentage of H929 cells undergoing
mitochondrial outer membrane permeabilization (MOMP) (top right) and Cell Death
(bottom right) under when treated with the same three drugs as the U266 and H929 cells. All
cells were incubated with the MEK1/2 inhibitor PD184352 and the Chk1 inhibitor CEP3891
for 24 hours followed by the Bcl-2 inhibitor HA14-1 for 24 hours before results were
analyzed. In all three MM cell lines, co-administration of HA14-1 with the MEK1/2 and
Chk1 inhibitors results in a higher degree of cell death in MM cells.
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3.3 Co-administration of HA14-1 Overcomes Bcl-2-mediated Protection from Cell
Death Induced by the MEK1/2/Chk1 Inhibitor Regimen in MM Cells
To test whether HA14-1 antagonizes Bcl-2 to overcome its anti-apoptotic function
against the CEP3981/PD184352 regimen in Bcl-2 over-expressing cells, we exposed the
Bcl-2 over-expressing U266 cells to minimally toxic concentrations of the
CEP3891/PD184352 regimen with HA14-1 (2.5 μM; 48 hours). Treatment of the Bcl-2
over-expressing U266 cells with the CEP3891/PD184352/HA14-1 combination resulted
in a significantly greater cell death compared to the CEP3891/PD184352 regimen
(P<0.01) (Figure 6). We further confirmed these results in ectopic human Bcl-2 overexpressing RPMI8226 cells, which were treated with CEP3891 (500 nM)/PD184352 (2.5
μM) /HA14-1 (1 μM) (P<0.01) (Figure 7).
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Figure 6. HA14-1 restores sensitivity of the Bcl-2 over-expressing U266 cells to the
MEK1/2/Chk1 inhibitor regimen.
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Figure 7. HA14-1 significantly increases mitochondrial damage and cell death in RPMI8226
cells ectopically over-expressing human Bcl-2.

3.4 HA14-1 Enhances Activation of the Caspase Cascade Triggered by the
PD184352/CEP3891 Regimen in MM Cells
We next examined the molecular events which are associated with potentiation of
PD184352/CEP3891 lethality by HA14-1. To this end, Western blot analysis was
performed to compare effects of the CEP3891/PD184352 regimen in the absence and
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presence of HA-14-1 regarding activation of caspase-9 and caspase-3, as well as resulting
PARP cleavage in both U266 and H929 MM cells.
In U266 cells, exposure to PD187352 and CEP3891 markedly induced cleavage
of caspase-9, caspase-3, and PARP, while co-administration of HA14-1 further lead to a
modest, but clear, increase in these events (Figure 8). A similar phenomenon was
observed in the H929 MM cell line (Figure 9).

Figure 8. HA14-1 modestly increases activation/cleavage of caspase-9, caspase-3 and PARP
cleavage in U266 cells exposed to the PD184352/CEP3891 regimen.
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Figure 9. HA14-1 slightly enhances cleavage of caspase-9, caspase-3 and PARP in H929 cells
treated with PD184352/CEP3891.

3.5 HA14-1 Re-sensitizes Bcl-2 Over-expressing MM cells to Activation of the
Caspase Cascade Induced by the Regimen Combining MEK1/2 and Chk1 Inhibitors
We then tested whether the ability of Bcl-2 over-expressing MM cells
overcoming resistance to the CEP3891/PD184352 regimen with HA14-1 is associated
with restoration of the capacity of this regimen to activate apoptotic signaling. In this
context, it was observed that co-administration of HA14-1 with CEP3891/PD184352
markedly enhanced cleavage/activation of caspases 9 and 3 and degradation of PARP
when compared to the PD184352/CEP3891 regimen (Figure 10). These findings indicate
that ectopic expression of Bcl-2 generates a protective mechanism against activation of
the caspase cascade triggered by the MEK1/2/Chk1 inhibitor regimen, while HA14-1, by
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binding to and disabling function of over-expressed Bcl-2, restores sensitivity of these
cells to such a regimen.

Figure 10. The capacity of the PD184352/CEP3891 regimen to induce activation of caspase
cascade can be restored by HA14-1 in Bcl-2 over-expressing MM cells.

3.6 Co-treatment with MEK1/2 and Chk1 Inhibitors Blocks ERK-mediated BimEL
Phosphorylation and Degradation in MM cells, while these Events are not Affected
by HA-14-1
Our group previously reported that exposure of MM cells to the Chk1 inhibitor
UCN-01 results in a marked increase in phosphorylation of ERK1/2, which is blocked by
the co-administration of the MEK1/2 inhibitor PD184352. We have also demonstrated
that UCN-01 treatment induces phosphorylation and degradation of BimEL and that coadministration of PD184352 dramatically blocks phosphorylation and down-regulation of
21

BimEL induced by UCN-01. Furthermore, knockdown of BimEL by shRNA diminishes
lethality of PD184352/UCN-01 in MM cells, indicating a critical functional role of BimEL
in apoptosis induced by this regimen.8,20
In this study, we observed that exposure of U266 cells to the novel, more selective
Chk1 inhibitor CEP3891 (400 nM, 48 hours) also resulted in marked increase in
phosphorylation of ERK1/2 and phosphorylation/degradation of BimEL. These events
were largely blocked by the co-administration of 5 μM PD184352 (Figure 11). However,
there is no significant difference in changes of ERK phosphorylation and Bim EL
expression mediated by the CEP3891/PD184352 regimen in either absence or presence of
HA14-1, while HA14-1 treatment alone resulted in a modest decrease in BimEL level
(Figure 11).

Figure 11. PD184352 prevents ERK-mediated BimEL phosphorylation and degradation
induced by CEP3891, an event not affected by co-administration of HA14-1 in U266 cells.
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Similar events in ERK1/2 and BimEL phosphorylation/degradation were observed
in another MM cell line H929 when exposed to the CEP3891/PD184352 regimen with or
without HA14-1 (Figure 12).

Figure 12. Co-administration of HA14-1 does not interfere with changes in ERK
phosphorylation and BimEL expression in H929 cells exposed to PD184352/CEP3891.

3.7 HA14-1 Fails to Modify ERK Inactivation and BimEL Accumulation Mediated
by the CEP3891/PD184352 Regimen in Bcl-2 Over-expressing MM Cells
Since HA14-1 was able to restore sensitivity of Bcl-2 over-expressing MM cells
to the PD184352/CEP3891 regimen, we further tested whether this Bcl-2 antagonist will
affect ERK phosphorylation statues and BimEL levels in this setting. Bcl-2 overexpressing U266 cells displayed similar patterns as noted in the parental U266 cells, in
which PD184352 almost completely blocked ERK1/2 phosphorylation in response to
CEP3891, accompanied by BimEL accumulation, while there is no notable influence by
co-adminsitration of HA-14-1 (Figure 13). Similar results were found in the Bcl-2 overexpressing RPMI8226 cells (data not shown). Together, these results suggest that HA141 may act to interrupt Bcl-2 function (e.g., binding of BimEL), rather than to modify
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expression of BimEL, a BH3-only protein that plays a critical role in mediation of
apoptotic signaling induced by the MEK1/2/Chk1 inhibitor strategy.

Figure 13. HA14-1 does not change the patterns of ERK phosphorylation and Bim EL
expression in the ectopic Bcl-2 over-expressing U266 cells.

DISCUSSION
Previous work from our group has shown that the MEK1/2 inhibitor, PD184352,
blocks Chk1 inhibitors (e.g., UCN-01) induced phosphorylation/activation of
MEK1/2/ERK1/2 in multiple myeloma cells, leading to a dramatic increase in apoptosis.
This lethal interaction could be largely blocked by ectopic over-expression of either Bcl-2
or Bcl-xL.8,29 The Bcl-2 oncoprotein is commonly over-expressed in hematological
malignancies including multiple myeloma, providing a cell with protection from
apoptosis induced by various therapies. Thus, in order to further develop this new
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therapeutic strategy, it is important to define functional roles of Bcl-2 and to investigate
an additional approach to ensure the efficacy of this strategy in myeloma cells with overexpression of Bcl-2. Post-translational regulation of the pro-apoptotic protein BimEL is
primarily mediated by MEK1/2/ERK1/2 signals.11 Activated ERK1/2 can mediate
multiple phosphorylations of BimEL, leading to its ubiquitination and proteosomal
degradation.14,15 We have also demonstrated that exposure of MM cells to UCN-01
induces ERK activation-associated BimEL phosphorylation and degradation, while these
events are blocked by PD184352, resulting in marked BimEL accumulation. Moreover,
prevention of BimEL expression by shRNA significantly diminishes apoptotic signaling
cascade triggered by the PD184352/UCN-01 regimen. Therefore, potentiation of Chk1
inhibitor lethality by MEK1/2 inhibitors seems to involve loss of balance between antiand pro-apoptotic Bcl-2 family proteins.
In the present studies, we employed CEP3891, a novel and highly selective Chk1
inhibitor under preclinical evaluation, in place of UCN-01, which exhibits multiple
actions excluding inhibition of Chk1. Notably, exposure of MM cells to CEP3891
induces phosphorylation/activation of ERK1/2, while co-administration with the MEK1/2
inhibitor PD184352 blocks ERK1/2 activation and induces apoptosis in several human
myeloma cell lines. These results are consistent with those found in the case of UCN-01.
We also found that ectopic over-expression of Bcl-2 significantly blocks apoptosis
induced by the newer MEK1/2/Chk1 inhibitor (i.e., PD184352/CEP3891) regimen.
In order to investigate the functional roles of Bcl-2, and overcome the resistance
mediated by Bcl-2 in the Bcl-2 over-expressing cells, we tested a strategy that targets and
inhibits the function of Bcl-2 by using the Bcl-2 antagonist HA14-1. HA14-1 is a small
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molecule inhibitor, designed as a Bcl-2 ligand based on the three dimensional structure of
the Bcl-2 protein.29 HA14-1 inhibits function of Bcl-2 by binding to the surface pocket of
Bcl-2, thereby disrupting its binding with with Bax/Bak and free the latter to trigger
MOMP and apoptosis. Previous reports have demonstrated that HA14-1 blocks the
function of the anti-apoptotic Bcl-2 family proteins, thereby activating caspase-9 and
caspase-3 to induce apoptosis in tumor cells.
In the present work, we investigated the function of Bcl-2 by co-administering
HA14-1 with the PD184352/CEP3891 regimen both in parental MM cells and in their
counterparts that ectopically over-express Bcl-2. In doing so, we monitored three
endpoints: 1) Mitochondrial outer membrane permeabilization. 2) Extent of apoptosis. 3)
ERK-mediated BimEL phosphorylation/activation as well as total abundance. The results,
by comparing Bcl-2 over-expressing MM cells with their parental cells, indicate that coadministration of HA14-1 further increases apoptosis synergistically induced by
PD184352 and CEP3891 in MM cell lines. More importantly, ectopic over-expression of
Bcl-2 in U266 or RPMI8226 myeloma cells markedly blunt lethality of the
PD184352/CEP3891 regimen, while co-treatment with HA14-1 is able to overcome overexpressing Bcl-2 mediated resistance toward the PD184352/CEP3891 regimen. The
following is a proposed mechanistic model for our study (Figure 14).
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Figure 14. Displayed is a proposed model for the interactions between key apoptotic proteins
and our applied drug treatments, the Chk1 inhibitors (UCN-01, CEP3891, AZD7762), the
MEK1/2 inhibitors (PD184352, PD98059, U0126), and the small molecule Bcl-2 inhibitor
(HA14-1). ERK1/2 activation by Chk1 inhibitors plays a cytoprotective role through
mediating Bim phosphorylation and subsequent degradation. Remarkably, coadministration of MEK1/2 inhibitors blocks Chk1 inhibitor-induced ERK1/2 activation and
Bim phosphorylation/degradation, leading to an increase in the amount of Bim associated
with Bcl-2 and Bcl-xL. This disables the anti-apoptotic function of Bcl-2 and Bcl-xL. In MM
cells over-expressing Bcl-2 anti-apoptotic proteins, HA14-1 acts to block the anti-apoptotic
function of Bcl-2, thereby releasing Bcl-2 interference of Bax/Bak interaction and
downstream intrinsic apoptotic events. These events produced by HA14-1 re-sensitize MM
cells to the MEK1/2/Chk1 inhibitor regimen.

First, we observe a greater extent of cell death and mitochondrial outer membrane
permeabilization in cells treated with the PD184352/CEP3891/HA14-1 regimen
compared with the PD184352/CEP3891 regimen in parental U266 cells. These results
were also obtained in two different MM cell lines, RPMI8226, and H929. Furthermore,
we found that the increase of cell death and mitochondrial outer membrane
permeabilization in Bcl-2 over-expressing cells treated PD184352/CEP3891/HA14-1,
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compared with the PD184352/CEP3891 regimen, is significantly more profound in the
cells with ectopic expression of Bcl-2 versus their parental cells. These findings indicate
that Bcl-2 plays an important role in prevention of MM cells from apoptosis induced by
the combination strategy of MEK1/2/Chk1 inhibitors.
Second, Western blot data suggests that the co-administration of HA14-1 with the
PD184352/CEP3891 regimen induces a slightly increased cleavage of caspase-9,
caspase-3, and PARP in U266 parental cells, compared with treatment with the
PD184352/CEP3891 regimen. This phenomenon was also observed in two other MM cell
lines: H929 and RPMI8226 (data not shown). In marked contrast, ectopic overexpression of Bcl-2 largely prevents cleavage of caspase-9, caspase-3, and PARP induced
by the PD184352/CEP3891 regimen, exposure to PD184352/CEP3891/HA14-1 results in
a significant increase in activation of this caspase cascade in the Bcl-2 over-expressed
MM cells. In conjunction, re-sensitization of Bcl-2 over-expressing MM cells to the
PD184352/CEP3891 regimen by HA14-1 is related to interruption of Bcl-2 anti-apoptotic
function, and thus restoration, of apoptotic signaling pathway to be activated by the novel
strategy combining MEK1/2 inhibitors with Chk1 inhibitors.
Third, upon results of Western blot analysis, there is no significant change in the
phosphorylation/degradation state of BimEL in both parental and Bcl-2 over-expressing
MM cells treated with PD184352/CEP3891/HA14-1 compared with cells treated with
PD184352/CEP3891. Therefore, HA14-1 acts to overcome the resistance caused by
ectopic expression of Bcl-2, which is unlikely through interference with ERK-mediated
BimEL phosphorylation and degradation. Since Bcl-2 binds tightly and sequesters proapoptotic Bcl-2 family proteins including BimEL, it is assumed that ectopic over-
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expressed Bcl-2 is capable of binding to and disabling more BimEL molecules. This may
explain why exposure of Bcl-2 over-expressing cells to the PD184352/CEP3891 regimen
only induces a limited degree of apoptosis while this regimen induces a marked BimEL
accumulation almost equally in the parental versus Bcl-2 over-expressing MM cells.
These results suggest that ectopic over-expressed Bcl-2 prevents MM cells from
lethality due to the MEK1/2/Chk1 inhibitor strategy by increased binding and
sequestration of up-regulated BimEL. Therefore, the approach using a Bcl-2 antagonist
like HA14-1 in conjunction with the PD184352/CEP3891 regimen significantly induces
apoptosis of the MM cells with over-expression of Bcl-2. Since HA14-1 binds to the
surface pocket of Bcl-2, where it also binds to the BH3-only protein BimEL, we presume
that administration of HA14-1 may release BimEL from association with Bcl-2, rendering
BimEL in its active/dephosphorylated form to activate Bax/Bak and induce MOMP,
restoring sensitivity of MM cells with over-expression of Bcl-2 to the MEK1/2/Chk1
combination strategy.
Although HA14-1 cannot be used in clinical evaluation, several Bcl-2 antagonists
(e.g., ABT737, ABT263, and GX15-070/Obatoclax) are developed and currently under
clinical evaluation. The findings in the present work demonstrate the functional role of
Bcl-2 in prevention of MM cells from lethality of the new strategy combining MEK1/2
and Chk1 inhibitors. They also may help to re-formulate this novel treatment for multiple
myeloma patients that exhibit resistance or no response to the MEK1/2/Chk1 inhibitor
regimen, particularly because of over-expression of Bcl-2. Several mechanistic issues
remain to be further addressed or validated, such as whether Bcl-2 antagonists like
HA14-1, do directly target at Bcl-2 and disable its ability to bind to and sequester pro-
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apoptotic proteins, particularly BimEL. The strategy combining clinically relevant
MEK1/2 inhibitors, Chk1 inhibitors, and Bcl-2 antagonists warrant further investigation,
particularly in multiple myeloma cells with over-expression of Bcl-2.
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